BR112016018633A2 - - Google Patents
Info
- Publication number
- BR112016018633A2 BR112016018633A2 BR112016018633A BR112016018633A BR112016018633A2 BR 112016018633 A2 BR112016018633 A2 BR 112016018633A2 BR 112016018633 A BR112016018633 A BR 112016018633A BR 112016018633 A BR112016018633 A BR 112016018633A BR 112016018633 A2 BR112016018633 A2 BR 112016018633A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1403093.6 | 2014-02-21 | ||
| GB201403093A GB201403093D0 (en) | 2014-02-21 | 2014-02-21 | Therapeutic compounds and their use |
| PCT/GB2015/050494 WO2015124941A1 (en) | 2014-02-21 | 2015-02-20 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016018633A2 true BR112016018633A2 (pt) | 2017-08-08 |
| BR112016018633B1 BR112016018633B1 (pt) | 2022-08-30 |
Family
ID=50482596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016018633-8A BR112016018633B1 (pt) | 2014-02-21 | 2015-02-20 | Pirazolopirimidina-5,7-diaminas como inibidores de cdk, seus usos, composição farmacêutica e seu método de preparação, e método in vitro para inibir a função de quinase dependente de ciclina em uma célula |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9932344B2 (pt) |
| EP (1) | EP3107914B8 (pt) |
| JP (1) | JP6498212B2 (pt) |
| CN (1) | CN106103445B (pt) |
| AU (1) | AU2015220560B2 (pt) |
| BR (1) | BR112016018633B1 (pt) |
| CA (1) | CA2939786C (pt) |
| CY (1) | CY1121588T1 (pt) |
| DK (1) | DK3107914T3 (pt) |
| ES (1) | ES2721268T3 (pt) |
| GB (1) | GB201403093D0 (pt) |
| HR (1) | HRP20190685T1 (pt) |
| HU (1) | HUE043122T2 (pt) |
| LT (1) | LT3107914T (pt) |
| ME (1) | ME03427B (pt) |
| NZ (1) | NZ724323A (pt) |
| PL (1) | PL3107914T3 (pt) |
| PT (1) | PT3107914T (pt) |
| RS (1) | RS58704B1 (pt) |
| SI (1) | SI3107914T1 (pt) |
| SM (1) | SMT201900266T1 (pt) |
| TR (1) | TR201905647T4 (pt) |
| WO (1) | WO2015124941A1 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2966164C (en) | 2014-10-31 | 2023-10-17 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| EP3233842B1 (en) | 2014-12-17 | 2025-03-26 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists |
| CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| EP3309163A4 (en) | 2015-06-15 | 2019-01-09 | UBE Industries, Ltd. | SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE |
| US20200123499A1 (en) | 2015-12-02 | 2020-04-23 | Massachusetts Institute Of Technology | Method for efficient generation of neurons from non-neuronal cells |
| KR102411150B1 (ko) | 2016-08-31 | 2022-06-21 | 아지오스 파마슈티컬스 아이엔씨. | 세포 대사 과정의 억제제 |
| CN117946114A (zh) | 2017-07-28 | 2024-04-30 | 武田药品工业株式会社 | Tyk2抑制剂与其用途 |
| CA3075477A1 (en) * | 2017-08-07 | 2019-02-14 | Joint Stock Company "Biocad" | Novel heterocyclic compounds as cdk8/19 inhibitors |
| US20200197392A1 (en) * | 2017-08-15 | 2020-06-25 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating tuberous sclerosis complex |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| TWI703149B (zh) * | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| CN112313235A (zh) * | 2018-04-11 | 2021-02-02 | 奎利恩特有限公司 | 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| MX2020014245A (es) | 2018-06-29 | 2021-05-12 | Kinnate Biopharma Inc | Inhibidores de quinasas dependientes de ciclinas. |
| MY210039A (en) | 2018-10-30 | 2025-08-22 | Kronos Bio Inc | Compounds, compositions, and methods for modulating cdk9 activity |
| US12304913B2 (en) | 2018-11-14 | 2025-05-20 | Ube Industries, Ltd. | Dihydropyrrolopyrazole derivative |
| CN109860354B (zh) * | 2018-12-28 | 2020-05-19 | 南京邮电大学 | 同质集成红外光子芯片及其制备方法 |
| WO2020186196A1 (en) * | 2019-03-13 | 2020-09-17 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
| AU2020311297A1 (en) * | 2019-07-10 | 2022-02-03 | Aucentra Therapeutics Pty Ltd | DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS |
| WO2021087138A1 (en) * | 2019-10-29 | 2021-05-06 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7) |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| US20230106032A1 (en) * | 2020-03-06 | 2023-04-06 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
| US20230158159A1 (en) * | 2020-04-24 | 2023-05-25 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
| JP7657943B2 (ja) * | 2021-01-22 | 2025-04-07 | 上海海雁医薬科技有限公司 | 置換ピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体、その組成物及び医薬上の使用 |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| GB202108572D0 (en) * | 2021-06-16 | 2021-07-28 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| JP2024543136A (ja) * | 2021-11-24 | 2024-11-19 | クロノス バイオ インコーポレイテッド | （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態 |
| WO2024102447A1 (en) * | 2022-11-10 | 2024-05-16 | Emory University | Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases |
| EP4671245A1 (en) * | 2023-02-20 | 2025-12-31 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE |
| WO2024175024A1 (zh) * | 2023-02-21 | 2024-08-29 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025006569A1 (en) | 2023-06-27 | 2025-01-02 | Arvinas Operations, Inc. | Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer |
| WO2025057087A1 (en) | 2023-09-11 | 2025-03-20 | Assia Chemical Industries Ltd. | Solid state forms of samuraciclib |
| WO2025208104A1 (en) * | 2024-03-29 | 2025-10-02 | The Translational Genomics Research Institute | Cdk7 inhibitors and methods of use thereof |
| WO2025208097A1 (en) * | 2024-03-29 | 2025-10-02 | The Translational Genomics Research Institute | Cdk7 inhibitors and methods of use thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| CA2497440C (en) | 2002-09-04 | 2011-03-22 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| EP1592689A4 (en) | 2003-01-31 | 2008-12-24 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| KR20050115252A (ko) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | 피라졸로[1,5-ａ]피리미딘 유도체 |
| WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JO2478B1 (en) | 2003-06-19 | 2009-01-20 | جانسين فارماسوتيكا ان. في. | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists |
| CA2627623C (en) * | 2005-10-06 | 2014-04-22 | Schering Corporation | Methods for inhibiting protein kinases |
| EP2170073A4 (en) | 2007-06-05 | 2011-07-27 | Univ Emory | SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES |
| WO2011068667A1 (en) * | 2009-12-04 | 2011-06-09 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
| PT3409278T (pt) * | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de proteína cinase heterocíclicos |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP2634189A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
-
2014
- 2014-02-21 GB GB201403093A patent/GB201403093D0/en not_active Ceased
-
2015
- 2015-02-20 LT LTEP15706282.9T patent/LT3107914T/lt unknown
- 2015-02-20 HR HRP20190685TT patent/HRP20190685T1/hr unknown
- 2015-02-20 WO PCT/GB2015/050494 patent/WO2015124941A1/en not_active Ceased
- 2015-02-20 HU HUE15706282A patent/HUE043122T2/hu unknown
- 2015-02-20 BR BR112016018633-8A patent/BR112016018633B1/pt active IP Right Grant
- 2015-02-20 PT PT15706282T patent/PT3107914T/pt unknown
- 2015-02-20 SM SM20190266T patent/SMT201900266T1/it unknown
- 2015-02-20 US US15/117,982 patent/US9932344B2/en active Active
- 2015-02-20 ME MEP-2019-119A patent/ME03427B/me unknown
- 2015-02-20 AU AU2015220560A patent/AU2015220560B2/en active Active
- 2015-02-20 SI SI201530714T patent/SI3107914T1/sl unknown
- 2015-02-20 TR TR2019/05647T patent/TR201905647T4/tr unknown
- 2015-02-20 CN CN201580011502.7A patent/CN106103445B/zh active Active
- 2015-02-20 NZ NZ724323A patent/NZ724323A/en unknown
- 2015-02-20 ES ES15706282T patent/ES2721268T3/es active Active
- 2015-02-20 DK DK15706282.9T patent/DK3107914T3/en active
- 2015-02-20 JP JP2016553387A patent/JP6498212B2/ja active Active
- 2015-02-20 CA CA2939786A patent/CA2939786C/en active Active
- 2015-02-20 EP EP15706282.9A patent/EP3107914B8/en active Active
- 2015-02-20 RS RS20190487A patent/RS58704B1/sr unknown
- 2015-02-20 PL PL15706282T patent/PL3107914T3/pl unknown
-
2018
- 2018-03-30 US US15/941,063 patent/US10414772B2/en active Active
-
2019
- 2019-04-17 CY CY20191100425T patent/CY1121588T1/el unknown
- 2019-09-04 US US16/559,735 patent/US10927119B2/en active Active
-
2021
- 2021-02-15 US US17/175,780 patent/US11566029B2/en active Active
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) ; EMORY UNIVERSITY (US) ; IP2IPO INNOVATIONS LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) ; EMORY UNIVERSITY (US) ; IP2IPO INNOVATIONS LIMITED (GB) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2015, OBSERVADAS AS CONDICOES LEGAIS |